Search results for "Pharmacogenetics"

showing 10 items of 90 documents

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

2009

Abstract Introduction Hypersensitivity reaction to abacavir (a powerful inverse transcriptase inhibitor) is a serious adverse effect that limits its use in antiretroviral treatment and requires a high level of clinical surveillance. Certain haplotypes of the primary histocompatibility complex proteins (HLA-B*5701) are very significant predictors of the risk of hypersensitivity to this drug. The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA-B*5701 allele. Method A retrospective study was conducted in all HIV-1 positive adult patients infected treated with abacavir between January 2000 and December 2007, in Department 6…

AdultMalemedicine.medical_specialtyFeverGenotypeAnti-HIV AgentsGastrointestinal DiseasesGenes MHC Class IHIV InfectionsPharmacotherapyAbacavirInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAdverse effectAgedRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedRashDideoxynucleosidesHypersensitivity reactionHLA-B AntigensImmunologyHIV-1Reverse Transcriptase InhibitorsFemaleDrug Eruptionsmedicine.symptombusinessPharmacogeneticsmedicine.drugFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
researchProduct

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.

2015

Lung transplant patients present important variability in immunosuppressant blood concentrations during the first months after transplantation. Pharmacogenetics could explain part of this interindividual variability. We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients). The genotype was correlated to the trough blood drug concentrations corrected for dose and body weight (C0/Dc). The ABCB1 variant in rs1045642 was associated with significantly hig…

Adultmedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatment<i>P</i>-glycoproteinSingle-nucleotide polymorphismPharmacologyP-glycoproteinGastroenterologyPolymorphism Single NucleotideCatalysisMycophenolic acidTacrolimusArticlelcsh:ChemistryInorganic ChemistryInternal medicineBlood drugmedicinelung transplantationLung transplantationCytochrome P-450 CYP3AHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopybiologyOrganic ChemistryGeneral MedicineMiddle AgedMycophenolic AcidTacrolimusMultidrug Resistance-Associated Protein 2Computer Science ApplicationsTransplantationlcsh:Biology (General)lcsh:QD1-999Pharmacogeneticsbiology.proteinMultidrug Resistance-Associated ProteinsSLCO1B1PharmacogeneticsImmunosuppressive Agentsmedicine.drugInternational journal of molecular sciences
researchProduct

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A&gt;G genotype on tacrolimus dose requirements in liver tran…

2013

Objective A meta-analysis was carried out of publishedstudies on the effect of the CYP3A5 6986A>Gpolymorphism in liver donors and transplant recipientson tacrolimus pharmacokinetics.Methods Cohort studies that evaluated the relationshipbetween the CYP3A5 polymorphism in liver donors andtransplant recipients and tacrolimus, trough bloodconcentration normalized for the daily dose (C) perkilogram body weight (D) (C/D, ng/ml/mg/kg/day) up to1 year after transplantation, were included. Data were notrestricted by patient age or the language or journal ofpublication. A literature search was conducted using theCochrane Library, MEDLINE, EMBASE, and grey literature,and articles published up to 24 Ap…

Adultmedicine.medical_specialtyAdolescentGenotypemedicine.medical_treatmentLiver transplantationPolymorphism Single NucleotideGastroenterologyTacrolimusYoung AdultInternal medicineGenotypeLiving DonorsGeneticsCytochrome P-450 CYP3AHumansMedicineGeneral Pharmacology Toxicology and PharmaceuticsCYP3A5Molecular BiologyGenetics (clinical)AgedAged 80 and overTransplantationbusiness.industryGenetic VariationMiddle AgedTacrolimusLiver TransplantationTransplantationMeta-analysisImmunologyMolecular MedicinebusinessImmunosuppressive AgentsPharmacogeneticsCohort studyPharmacogenetics and Genomics
researchProduct

Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatm…

2005

Familial hypercholesterolaemia (FH) is an autosomal dominant disease characterized by elevated levels of low-density lipoprotein-cholesterol (LDL-C). Phenotypic expression is highly variable, being influenced by diet, age, gender, body mass index, apolipoprotein E genotype and type of LDL-receptor gene mutation. Microsomal triglyceride (TG) transfer protein (MTP) is a protein involved in lipid metabolism. Polymorphism MTP -493 GT has been shown to modulate lipid levels in several populations. To analyse the effect of this polymorphism in the lipid phenotype expression of FH and treatment response, we studied a sample of 222 Spanish FH patients, of whom 147 were studied before and after trea…

Apolipoprotein EMaleAtorvastatinPolymerase Chain ReactionMicrosomal triglyceride transfer proteinBody Mass Indexchemistry.chemical_compoundAtorvastatinGeneral Pharmacology Toxicology and PharmaceuticsPromoter Regions GeneticGenetics (clinical)Polymorphism Single-Stranded ConformationalGeneticsbiologyAutosomal dominant traitFastingLipoproteins LDLCholesterolPhenotypeMolecular Medicinelipids (amino acids peptides and proteins)Femalemedicine.drugmedicine.medical_specialtyHeterozygoteGenotypeLipoproteinsHyperlipoproteinemia Type IIApolipoproteins ESex FactorsInternal medicineGeneticsmedicineHumansPyrrolesMolecular BiologyAllelesTriglyceridesPolymorphism GeneticTriglycerideCholesterolGenetic VariationCholesterol LDLDNALipid MetabolismEndocrinologychemistryHeptanoic AcidsPharmacogeneticsMutationbiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCarrier ProteinsBody mass indexPharmacogeneticsPharmacogenetics and genomics
researchProduct

Alzheimer’s disease and genetics of inflammation: a pharmacogenomic vision

2007

Inflammation plays a key role in Alzheimer disease, and dissecting the genetics of inflammation may provide an answer to the possible treatment. The next-generation therapy is based on a pharmacogenomics that will reconure new approaches to a drug used on definite people with specific dosage. The translation of pharmacogenomics into clinical practice will allow bold steps to be taken toward personalized medicine. In response to tissue injury elicited by trauma or infection, the inflammatory response sets in as a complex network of molecular and cellular interactions, directed to facilitate a return to physiological homeostasis and tissue repair. The role of an individual’s genetic backgroun…

Apolipoprotein E2alzheimerInflammationDiseaseAlzheimer DiseaseGeneticsHumansMedicineSettore MED/05 - Patologia ClinicaClinical significancePhysiological HomeostasisInflammationPharmacologyGeneticsSettore MED/04 - Patologia Generalebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseToll-Like Receptor 4PharmacogeneticsPharmacogenomicsTLR4CytokinesMolecular MedicinePersonalized medicinemedicine.symptomAlzheimer's diseasebusiness
researchProduct

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.

2014

Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1 modify effect of such dose-adjustment strategy.Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off value of ≥60% was defined as hyporesponsiveness. Polymorphism of two cytochromes (CYP2C19, CYP2C9) and gene ABCB1 were determined. …

CYP2C9MaleMedicine (General)ATP Binding Cassette Transporter Subfamily BTiclopidinemedicine.medical_treatmentCYP2C19PharmacologyR5-920Percutaneous Coronary InterventionmedicinePotencyHumansProspective StudiesCYP2C19AlleleCYP2C9AllelesAgedCytochrome P-450 CYP2C9Medicine(all)Polymorphism GeneticDose-Response Relationship Drugbusiness.industryClopidogrel resistanceMicrofilament ProteinsPercutaneous coronary interventionABCB1Drug-Eluting StentsVASPMiddle AgedClopidogrelPhosphoproteinsClopidogrelCytochrome P-450 CYP2C19Drug-eluting stentPharmacogeneticsAutomotive EngineeringConventional PCIFemalebusinessCell Adhesion MoleculesPlatelet Aggregation InhibitorsClopidogrel resistance; VASP; CYP2C19; ABCB1; CYP2C9medicine.drugMedicina (Kaunas, Lithuania)
researchProduct

Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking

2015

Apigenin is a common dietary flavonoid with considerable cytotoxic activity in vitro and in vivo. Despite many mechanistic studies, less is known about resistance factors hampering apigenin's activity. We investigated the ATP-binding cassette (ABC) transporters BCRP/ABCG2, P-glycoprotein/ABCB1 and its close relative ABCB5. Multidrug-resistant cells overexpressing these ABC transporters were not cross-resistant toward apigenin. Moreover, apigenin inhibited not only P-glycoprotein but also BCRP by increasing cellular uptake of doxorubicin and synergistic inhibition of cell viability in combination with doxorubicin or docetaxel in multidrug-resistant cells. To perform in silico molecular docki…

Cancer ResearchAbcg2Protein ConformationEndocrinology Diabetes and MetabolismClinical BiochemistryATP-binding cassette transporterPharmacologyBiochemistryMicechemistry.chemical_compoundTranscriptional regulationCluster AnalysisImmunology and AllergyApigeninNutrition and DieteticsbiologyABCB5Drug Resistance MultipleNeoplasm ProteinsMolecular Docking SimulationOncologyBiochemistryApigeninMolecular Medicinemedicine.drugIn silicoImmunologyInhibitory Concentration 50Cell Line TumormedicineAnimalsHumansDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1RNA MessengerViability assayMolecular BiologyPharmacologyComputational BiologyPolyphenolsTransporterIn vitroHEK293 CellschemistryDoxorubicinDrug Resistance NeoplasmPharmacogeneticsPoster Presentationbiology.proteinATP-Binding Cassette TransportersThe Journal of Nutritional Biochemistry
researchProduct

Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene.

2003

Cushing's syndrome and systemic administration of glucocorticoids are associated with hypertension, but the underlying molecular mechanism is only partially understood. We have shown previously that dexamethasone downregulates the expression of the endothelial NO synthase (eNOS) gene in human endothelial cells and in the rat and that this may contribute to the blood pressure-raising effect of the steroid [Proc. Natl. Acad. Sci. USA 96 (1999) 13357]. In the current communication, we demonstrated that dexamethasone increased mean arterial blood pressure in wild-type C-57 Bl6 mice (eNOS+/+ mice), but had no effect on blood pressure in mice with a disrupted eNOS gene (eNOS-/- mice) derived from…

Cancer Researchmedicine.medical_specialtyEndotheliumNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryNitric Oxide Synthase Type IIBlood PressureBiologyKidneyNitric OxideBiochemistryDexamethasoneMiceDownregulation and upregulationEnosInternal medicinemedicineAnimalsEnzyme InhibitorsDexamethasoneMice KnockoutKidneyMyocardiumNitric Oxide Synthase Type IIIbiology.organism_classificationmedicine.anatomical_structureBlood pressureEndocrinologyLiverPharmacogeneticsHypertensionSystemic administrationNitric Oxide Synthasemedicine.drugNitric oxide : biology and chemistry
researchProduct

Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy

2011

Abstract Ethnopharmacological relevance A socio-economic burden associated with cancers is reported in Africa. Ethnopharmacological usages such as immune and skin disorders, inflammatory, and others chould be considered when selecting plants used to treat cancer, since these reflect disease states bearing relevance to cancer or a cancer symptoms. Materials and methods Documented compounds of Cameroonian medicinal plants were used as keywords in the National Cancer Institute (NCI) database to establish a library of cytotoxic compounds. Cellular and pharmacogenomic profiling was then performed for the 10 most cytotoxic natural products. By COMPARE and hierarchical cluster analyses, candidate …

Candidate geneMicroarrayCell SurvivalPharmacologyInhibitory Concentration 50chemistry.chemical_compoundCell Line TumorDrug DiscoveryAnimalsCluster AnalysisHumansMedicineCameroonRNA MessengerMedicinal plantsMedicine African TraditionalPharmacologyPlants MedicinalNatural productDose-Response Relationship DrugTraditional medicinebiologybusiness.industryGene Expression ProfilingPlumbaginbiology.organism_classificationAntineoplastic Agents PhytogenicGene Expression Regulation NeoplasticGene expression profilingchemistryDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsPlant PreparationsDiospyros crassiflorabusinessJournal of Ethnopharmacology
researchProduct

Pharmacogenomics: a tool to prevent and cure coronary heart disease.

2007

Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). This is supported by epidemiological studies which have thoroughly investigated the association between CHD and gene polymorphisms of the inflammatory molecules. Moreover, efforts to find elective therapy have not been rewarding and, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. A critical search of published literature has suggested few inflammatory genes directly involved in the risk to develop CHD and MI. The selected genes are, the pro- …

Candidate genepharmacogenomicLipoxygenaseLipopolysaccharide ReceptorsMyocardial InfarctionCoronary DiseaseDiseaseBioinformaticsRisk AssessmentPathogenesisRisk FactorsDrug DiscoverymedicinecytokineHumansGenetic Predisposition to DiseaseMyocardial infarctionTLR4PharmacologyInflammationPolymorphism Geneticbusiness.industryPatient SelectionCase-control studyCOXLOXmedicine.diseaseAtherosclerosisToll-Like Receptor 4Treatment OutcomePharmacogeneticsProstaglandin-Endoperoxide SynthasesPharmacogenomicsCase-Control StudiesImmunologyCytokinesReceptors ChemokineChemokinesbusinessRisk assessmentCD14CCR5PharmacogeneticsCurrent pharmaceutical design
researchProduct